Risk factor
Sufficiently resilient to price shocks
Profitability factor
Favourable price performance
About
Tianjin Tianyao Pharmaceuticals Co., Ltd. is a Chinese enterprise primarily engaged in the research, manufacturing, and export of active pharmaceutical ingredients (APIs) across the Asian market. The company's core product offerings include APIs and formulated drugs for corticosteroid, cardio cerebrovascular, and analgesic applications. Its extensive portfolio of bulk drug substances encompasses numerous compounds such as dexamethasone and its various salts and esters, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone and its derivatives, clobetasol propionate, betamethasone, and methylprednisolone. Based in Tianjin, China, Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE: 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.
Company Valuation
Based on key historical and expected multiples, the stock is slightly overvalued relative to its peers. In particular, the stock is overpriced on P/E, of fair value on EV